Investigating how PPARd affects immune cell function in tumors

The role of PPARd-controlled CIITA/MHCII expression in Treg's function in tumor immunity

NIH-funded research Salk Institute for Biological Studies · NIH-11167345

This study is looking at how a protein called PPARd affects special immune cells that help keep our immune system balanced, and it's using a special type of mouse to see how removing this protein from those cells changes their ability to fight tumors, which could lead to new ways to boost our immune response against cancer.

Quick facts

Grant typeR21 grant
Study typeNIH-funded research
Funding institutionSalk Institute for Biological Studies NIH-funded
Lab location1 site (La Jolla, UNITED STATES)
Project IDNIH-11167345 on NIH RePORTER

What this research studies

This research explores the role of a specific protein, PPARd, in regulating immune cells known as regulatory T cells (Tregs) that are crucial for maintaining immune balance and preventing autoimmune diseases. The study uses a unique mouse model where PPARd is selectively removed from Tregs to observe how this affects tumor growth and immune responses. By analyzing the behavior of these modified Tregs in the presence of tumors, researchers aim to understand how PPARd influences the immune system's ability to fight cancer. The findings could provide insights into new therapeutic strategies for enhancing anti-tumor immunity.

Who could benefit from this research

Good fit: Ideal candidates for this research are individuals with cancers that may benefit from enhanced anti-tumor immune responses.

Not a fit: Patients with autoimmune diseases unrelated to tumor immunity may not receive direct benefits from this research.

Why it matters

Potential benefit: If successful, this research could lead to improved cancer therapies by enhancing the immune system's ability to target and destroy tumors.

How similar studies have performed: Previous research has shown promising results in manipulating immune cell functions to improve cancer treatment, indicating potential success for this approach.

Where this research is happening

La Jolla, UNITED STATES

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions anti-cancer therapy
Last reviewed 2026-06-09 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.